We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Teva hits bull's eye with Cephalon.
- Authors
Carey, Karen
- Abstract
The article focuses on Petach Tikva's Teva that won the bid for Cephalon at 6.8 billion U.S. dollars against the bid of Valeant Pharmaceuticals of 5.7 billion U.S. dollars. It mentions the oncology, central nervous system and pain drug development projects of Cephalon including the phase 2 pan-B-cell lymphoma 2 inhibitor and lung cancer drug Obatoclax (GX15-070). It also notes the products currently being marketed by Cephalon including Provigil (sparlon) and Treanda.
- Subjects
UNITED States; TEVA (Company); CEPHALON Inc.; BAUSCH Health Cos. Inc.; LYMPHOMA treatment; PHARMACEUTICAL industry
- Publication
Nature Biotechnology, 2011, Vol 29, Issue 7, p561
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0711-561a